Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

KalVista Pharmaceuticals, Inc. - Common Stock (NQ:KALV)

11.09 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 15
Open 11.09
Bid (Size) 10.45 (25)
Ask (Size) 13.40 (8)
Prev. Close 11.09
Today's Range 11.09 - 11.09
52wk Range 7.300 - 15.50
Shares Outstanding 34,233,643
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference
From KalVista Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
+25.2%
+25.2%
1 Month
+2.0%
+2.0%
3 Month
+25.2%
+25.2%
6 Month
-6.3%
-6.3%
1 Year
+0.5%
+0.5%

More News

Read More
KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
This Box Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Super Micro Computer And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
KalVista Appoints Jeb Ledell as Chief Operating Officer
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust
From KalVista Pharmaceuticals, Inc.
Via Business Wire
KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology
From KalVista Pharmaceuticals, Inc.
Via Business Wire

Frequently Asked Questions

Is KalVista Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, KalVista Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does KalVista Pharmaceuticals, Inc. - Common Stock trade on?
KalVista Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for KalVista Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for KalVista Pharmaceuticals, Inc. - Common Stock is KALV on the Nasdaq Stock Market
What is the current price of KalVista Pharmaceuticals, Inc. - Common Stock?
The current price of KalVista Pharmaceuticals, Inc. - Common Stock is 11.09
When was KalVista Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of KalVista Pharmaceuticals, Inc. - Common Stock was at 04/02/25 04:00 PM ET
What is the market capitalization of KalVista Pharmaceuticals, Inc. - Common Stock?
The market capitalization of KalVista Pharmaceuticals, Inc. - Common Stock is 379.65M
How many shares of KalVista Pharmaceuticals, Inc. - Common Stock are outstanding?
KalVista Pharmaceuticals, Inc. - Common Stock has 380M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.